Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.

Biochemical and biophysical research communications - 29 Jun 2012

Sun Hui-Yong, Ji Feng-Qin

Abstract excerpt

Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor that has recently been approved in the US for the treatment of non-small cell lung carcinoma (NSCLC). Despite its outstanding safety and efficacy, several resistant mutations against crizotinib have been detected in the treatment of NSCLC. However, in contrast to the widely accepted mechanism of steric hindrance by mutations at the active site, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogen Bonding

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Share to Tyrosine

Source

Identifiers

PMID: 22659414
DOI: 10.1016/j.bbrc.2012.05.120

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.PMID 22659414Read ↗

F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular simulations.Semantic proximity Read ↗

Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation.Semantic proximity Read ↗

Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach.Semantic proximity Read ↗

L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.Semantic proximity Read ↗

Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific InhibitorsSemantic proximity Read ↗

Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.Semantic proximity Read ↗

A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants.Semantic proximity Read ↗

Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.Semantic proximity Read ↗

Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights.Semantic proximity Read ↗

Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.Semantic proximity Read ↗

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma KinaseSemantic proximity Read ↗

Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.